表紙
市場調查報告書
商品編碼
1028752

傳染病的分子診斷市場:症候群、Plex、位置、國家:COVID-19 影響和預測/分析、執行指南和定制(2021-2025)

Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021 - 2025

出版日期: | 出版商: Howe Sound Research | 英文 21 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

臨床診斷行業中傳染病分子診斷市場正處於創紀錄增長的邊緣。傳染病檢測直接受益於生物技術的爆炸性發展,尤其是基因組學。

本報告探討了傳染病的分子診斷市場,提供了市場概況、按症候群、Plex、位置和國家劃分的趨勢,以及進入市場的公司概況。

目錄

第 1 章市場指南

  • COVID-19 的戰略態勢邏輯和影響
  • 高管、營銷、銷售和業務發展人員指南
  • 管理顧問和投資顧問指南

第 2 章市場的介紹和定義

  • 什麼是分子診斷?
  • 診斷革命
  • 市場定義
    • 收入
  • 調查方法
    • 作者
    • 來源
  • 前景:醫療保健、IVD 行業和 COVID-19 大流行
    • 全球醫療保健支出
    • 診斷費用
    • 保險對診斷的重要作用

第 3 章傳染病-按疾病分類的市場分析

  • HIV-人類免疫缺陷病毒 (AIDS)
    • 病毒學
    • 診斷
    • 檢驗
    • 市場機會分析
  • HBV-B 型肝炎
    • 病毒學
    • 機制
    • 診斷
    • 市場機會分析
  • HCV-C 型肝炎
    • 分類方法
    • 結構
    • 分子生物學
    • 複製
    • 基因型
    • 市場機會分析
  • HPV-人乳頭瘤病毒
    • 病毒學
    • 診斷
    • 市場機會分析
  • 流感
    • 病毒學
    • 檢驗
    • 市場機會分析
  • CTGC-衣原體/淋病
    • 淋病
    • 衣原體
    • 檢驗
    • 市場機會分析
  • 結核病
    • 分枝桿菌
    • 診斷
    • 流行病學
    • 分子診斷測試
    • 市場機會分析
  • MRSA-耐甲氧西林金黃色葡萄球菌
    • 診斷
    • FDA 批准的分子檢測
    • 市場機會分析
  • VRE-萬古黴素耐藥腸球菌
    • 經 FDA 批准的 VRE 的分子診斷測試
    • 市場機會分析
  • 血液篩查
    • 血液採樣和檢測
    • FDA 批准的多重檢測
    • 市場機會分析
  • COVID-19
    • 體徵和症狀
    • 感染
    • 診斷
    • 預防
    • 管理
    • 預後
  • 流行病診斷
    • 風險管理-激發和傳播
    • 診斷技術-基於核酸
    • 診斷技術-免疫測定和血清學
    • 啟動時間和準備問題
    • 多重在大流行管理中的作用未被認識到

第 4 章行業概況

  • 充滿活力的市場參與者
    • 學術研究所
    • 診斷測試開發人員
    • 儀器供應商
    • 分銷商和試劑供應商
    • 獨立檢驗實驗室
    • 公共國家/地區研究所
    • 醫院實驗室
    • 從業者實驗室
    • 審計機構
    • 認證機構
  • 臨床檢測細分市場
    • 傳統的市場細分
    • 實驗室重點和細分
  • 產業結構
    • 醫院檢查分享
    • 規模經濟
    • 從業者實驗室
    • 醫生和 POCT

第 5 章主要公司簡介

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Aus Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • bioM?rieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Cepheid(now Danaher)
  • Chembio
  • Co Diagnostics
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin S.p.A
  • Eiken Chemical
  • Enzo Life Sciences, Inc
  • Eurofins Scientific
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics
  • Genedrive
  • Genetic Signatures
  • GenMark Dx
  • Grifols
  • Hibergene Diagnostics
  • Hologic
  • Illumina
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Luminex Corp
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech
  • Millipore Sigma
  • Mindray
  • Mobidiag
  • Nanomix
  • Operon
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Primerdesign
  • Prominex
  • Qiagen Gmbh
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Thermo Fisher Scientific Inc
  • Veramarx
  • Veredus Laboratories
  • Vir
  • XCR Diagnostics

第 6 章市場趨勢

  • 生長促進因素
    • 創造新市場的新基因型
    • 人口老齡化有益於所有診斷
    • 發展中國家推動傳染病分子診斷的發展
    • Point of Care-為什麼中心化正在失去動力
    • 自我檢查
    • 需要速度
    • COVID 大流行
  • 生長抑製因素
    • 低成本
    • 減少傳染病
    • 健康危害
    • 經濟增長提高了生活水平
  • 儀器儀表和自動化
    • 設備是市場份額的關鍵
    • 收縮器
    • Multiplex、Point of Care 和 Speed Factor
  • 診斷技術的發展
    • 膿毒症檢測市場-新方向
    • POCT/自我反省作為破壞力
    • 遺傳學——對所有已知感染的一種測試
    • 抗生素抗性基因-簡化診斷

第 7 章傳染病的分子診斷-最新進展

第 8 章全球傳染病分子診斷市場

  • 按國家/地區分列的全球市場概覽
    • Table-World Markets by Country
    • 圖表-按國家/地區劃分的世界市場
  • World Market-By Syndrome-概覽
    • Table-World Market-By 症候群
    • 圖表-世界市場-按症候群-標準/最後一年比較
    • 圖表-世界市場-按症候群-基年
    • 圖表-世界市場-按症候群-年末
    • 圖表-世界市場-按症候群-按年份額
    • Chart-World Marketplace-By Syndrome-Segment Growth
  • World Market-By Plex-概覽
    • Table-World Markets-By Plex
    • 圖表-世界市場-按 Plex-標準/最後一年比較
    • 圖表-世界市場-按Plex-基年
    • 圖表-世界市場-按Plex-年末
    • 圖表-世界市場-按 Plex-按年份額
    • Chart-World Marketplace-By Plex-Segment Growth
  • 世界市場-按位置-概覽
    • Table-World Markets-By Location
    • 圖表-世界市場-按位置-標準/最後一年比較
    • 圖表-世界市場-按位置-基準年
    • 圖表-世界市場-按地點-年末
    • 圖表-世界市場-按位置-按年份額
    • 圖表-世界市場-按位置-細分市場增長

第 9 章全球傳染病分子診斷市場-按症候群

  • 呼吸系統
  • 胃腸道
  • 腦膜炎/腦炎
  • 性傳播疾病
  • 其他

第 10 章全球傳染病分子診斷市場-由 Plex

  • 單叢
  • 雙工
  • 三重
  • 多路復用技術

第 11 章全球傳染病分子診斷市場-按位置

  • 醫院實驗室
  • 門診實驗室
  • 概念驗證
  • 其他

第 12 章附錄

目錄

OVERVIEW:

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like:

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Strategic Situation Analysis and Impact of COVID-19
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 What are Molecular Diagnostics?
  • 2.2 The Diagnostics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenues
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Market Analysis by Disease

  • 3.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.1.1 Virology
      • 3.1.1.1 Classification
      • 3.1.1.2 Structure and genome
      • 3.1.1.3 Tropism
      • 3.1.1.4 Replication cycle
      • 3.1.1.5 Genetic variability
    • 3.1.2 Diagnosis
    • 3.1.3 Testing
      • 3.1.3.1 Antibody tests
      • 3.1.3.2 Point of Care Tests (POCT)
      • 3.1.3.3 Antigen Tests
      • 3.1.3.4 Nucleic acid-based tests (NAT)
      • 3.1.3.5 Other tests used in HIV treatment
    • 3.1.4 Market Opportunity Analysis
  • 3.2 HBV - Hepatitis B
    • 3.2.1 Virology
      • 3.2.1.1 Genome
      • 3.2.1.2 Pathogenesis
      • 3.2.1.3 Hepatitis B virus replication
      • 3.2.1.4 Serotypes and genotypes
    • 3.2.2 Mechanisms
    • 3.2.3 Diagnosis
    • 3.2.4 Market Opportunity Analysis
  • 3.3 HCV - Hepatitis C
    • 3.3.1 Taxonomy
    • 3.3.2 Structure
      • 3.3.2.1 Genome
    • 3.3.3 Molecular biology
    • 3.3.4 Replication
    • 3.3.5 Genotypes
      • 3.3.5.1 Clinical importance
    • 3.3.6 Market Opportunity Analysis
  • 3.4 HPV - Human papillomavirus
    • 3.4.1 Virology
      • 3.4.1.1 E6/E7 proteins
      • 3.4.1.2 Role in cancer
      • 3.4.1.3 E2 research
      • 3.4.1.4 Latency period
      • 3.4.1.5 Clearance
    • 3.4.2 Diagnosis
      • 3.4.2.1 Cervical testing
      • 3.4.2.2 Oral testing
      • 3.4.2.3 Testing men
      • 3.4.2.4 Other testing
    • 3.4.3 Market Opportunity Analysis
  • 3.5 Influenza
    • 3.5.1 Virology
      • 3.5.1.1 Types of virus
      • 3.5.1.2 Influenzavirus A
      • 3.5.1.3 Influenzavirus B
      • 3.5.1.4 Influenzavirus C
      • 3.5.1.5 Structure, properties, and subtype nomenclature
      • 3.5.1.6 Replication
    • 3.5.2 Testing
      • 3.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.5.3 Market Opportunity Analysis
  • 3.6 CTGC - Chlamydia/Gonorhea
    • 3.6.1 Gonorrhea
      • 3.6.1.1 Diagnosis
      • 3.6.1.2 Screening
    • 3.6.2 Chlamydia
      • 3.6.2.1 Diagnosis
      • 3.6.2.2 Screening
    • 3.6.3 Testing
      • 3.6.3.1 Nucleic acid amplification tests (NAATs)
      • 3.6.3.2 Performance of NAAT Tests
    • 3.6.4 Market Opportunity Analysis
  • 3.7 Tuberculosis
    • 3.7.1 Mycobacteria
    • 3.7.2 Diagnosis
      • 3.7.2.1 Active tuberculosis
      • 3.7.2.2 Latent tuberculosis
    • 3.7.3 Epidemiology
    • 3.7.4 Molecular Diagnostic Tests
    • 3.7.5 Market Opportunity Analysis
  • 3.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.8.1 Diagnosis
    • 3.8.2 FDA Approved Molecular Tests
    • 3.8.3 Market Opportunity Analysis
  • 3.9 VRE - Vancomycin-resistant Enterococcus
    • 3.9.1 FDA Approved MDx Tests for VRE
    • 3.9.2 Market Opportunity Analysis
  • 3.10 Blood Screening
    • 3.10.1 Collection and Testing
    • 3.10.2 FDA Approved Multiplex Assays
    • 3.10.3 Market Opportunity Analysis
  • 3.11 COVID-19
    • 3.11.1 Signs and symptoms
    • 3.11.2 Transmission
    • 3.11.3 Diagnosis
    • 3.11.4 Prevention
    • 3.11.5 Management
    • 3.11.6 Prognosis
  • 3.12 Pandemic Diagnostics
    • 3.12.1 Risk Management - Spark and Spread
    • 3.12.2 Dx Technology - Nucleic Acid Based
    • 3.12.3 Dx Technology - Immunoassay & Serology
    • 3.12.4 Time to Market and Preparedness Issues
    • 3.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Distributor and Reagent Supplier
    • 4.1.5 Independent Testing Lab
    • 4.1.6 Public National/regional lab
    • 4.1.7 Hospital lab
    • 4.1.8 Physician Office Labs
    • 4.1.9 Audit Body
    • 4.1.10 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Profiles of Key MDx Companies

  • 5.1 Abacus Diagnostica
  • 5.2 Abbott Diagnostics
  • 5.3 Accelerate Diagnostics
  • 5.4 Ador Diagnostics
  • 5.5 Akonni Biosystems
  • 5.6 Alveo Technologies
  • 5.7 Applied BioCode
  • 5.8 Aus Diagnostics
  • 5.9 Beckman Coulter Diagnostics
  • 5.10 Becton, Dickinson and Company
  • 5.11 Binx Health
  • 5.12 Biocartis
  • 5.13 bioMérieux Diagnostics
  • 5.14 Bio-Rad Laboratories, Inc
  • 5.15 Bosch Healthcare Solutions GmbH
  • 5.16 Cepheid (now Danaher)
  • 5.17 Chembio
  • 5.18 Co Diagnostics
  • 5.19 Credo Diagnostics Biomedical
  • 5.20 Cue Health
  • 5.21 Curetis N.V. / Curetis GmbH
  • 5.22 Diagenode Diagnostics
  • 5.23 Diascopic
  • 5.24 Diasorin S.p.A
  • 5.25 Eiken Chemical
  • 5.26 Enzo Life Sciences, Inc
  • 5.27 Eurofins Scientific
  • 5.28 Fluxergy
  • 5.29 Fulgent Genetics
  • 5.30 Fusion Genomics
  • 5.31 Genedrive
  • 5.32 Genetic Signatures
  • 5.33 GenMark Dx
  • 5.34 Grifols
  • 5.35 Hibergene Diagnostics
  • 5.36 Hologic
  • 5.37 Illumina
  • 5.38 Immunexpress
  • 5.39 Inflammatix
  • 5.40 Invetech
  • 5.41 Janssen Diagnostics
  • 5.42 Karius
  • 5.43 Lexagene
  • 5.44 LightDeck Diagnostics
  • 5.45 Luminex Corp
  • 5.46 Lumos Diagnostics
  • 5.47 Mammoth Biosciences
  • 5.48 Maxim Biomedical
  • 5.49 Meridian Bioscience
  • 5.50 Mesa Biotech
  • 5.51 Millipore Sigma
  • 5.52 Mindray
  • 5.53 Mobidiag
  • 5.54 Nanomix
  • 5.55 Operon
  • 5.56 Oxford Nanopore Technologies
  • 5.57 Panagene
  • 5.58 Perkin Elmer
  • 5.59 Primerdesign
  • 5.60 Prominex
  • 5.61 Qiagen Gmbh
  • 5.62 Quantumdx
  • 5.63 Quidel
  • 5.64 Roche Molecular Diagnostics
  • 5.65 Saw Diagnostics
  • 5.66 Seegene
  • 5.67 Siemens Healthineers
  • 5.68 Sona Nanotech
  • 5.69 SpeeDx
  • 5.70 T2 Biosystems
  • 5.71 Thermo Fisher Scientific Inc
  • 5.72 Veramarx
  • 5.73 Veredus Laboratories
  • 5.74 Vir
  • 5.75 XCR Diagnostics

6 Market Trends

  • 6.1 Factors Driving Growth
    • 6.1.1 New Genotypes Creating New Markets
    • 6.1.2 Aging Population a Boon for All Diagnostics
    • 6.1.3 Developing World Driving ID Dx Growth
    • 6.1.4 Point of Care - Why Centralization is Losing Steam
    • 6.1.5 Self Testing
    • 6.1.6 The Need for Speed
    • 6.1.7 The COVID Pandemic
  • 6.2 Factors Limiting Growth
    • 6.2.1 Lower Costs
    • 6.2.2 Infectious Disease is Declining
    • 6.2.3 Wellness Hurts
    • 6.2.4 Economic Growth improves Living Standards
  • 6.3 Instrumentation and Automation
    • 6.3.1 Instruments Key to Market Share
    • 6.3.2 The Shrinking Machine
    • 6.3.3 Multiplex, Point of Care and The Speed Factor
  • 6.4 Diagnostic Technology Development
    • 6.4.1 The Sepsis Testing Market - A New Direction?
    • 6.4.2 POCT/Self Testing as a Disruptive Force
    • 6.4.3 The Genetics Play - One Test for All Known Infections
    • 6.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

7 Molecular Dx - Infectious Disease Recent Developments

  • 7.1 Recent Developments - Importance and How to Use This Section
    • 7.1.1 Importance of These Developments
    • 7.1.2 How to Use This Section
  • 7.2 Home Test Company Prenetics to go Public
  • 7.3 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • 7.4 Lucira Health Posts Revenue Growth on OTC C19 Test
  • 7.5 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • 7.6 Talis Biomedical Discusses Point-of-Care
  • 7.7 Roche to Acquire GenMark Diagnostics for $1.8B
  • 7.8 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 7.9 Hologic to Acquire Mobidiag
  • 7.10 Lucira Health Focuses on User Friendly Approach to Home Testing
  • 7.11 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 7.12 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 7.13 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 7.14 Mammoth Biosciences Developing Pathogen Detection Tech
  • 7.15 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 7.16 Scanogen Developing 90 Minute Infection Test
  • 7.17 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 7.18 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 7.19 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 7.20 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 7.21 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 7.22 Lumos Diagnostics Closes $15M Series A Funding
  • 7.23 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
  • 7.24 New Genomic Tests Diagnose Deadly Infections Faster
  • 7.25 Biotia Raises $2.4M Seed Round
  • 7.26 STDs resurge in US
  • 7.27 Ares Genetics signs R&D agreement with leading global IVD corporation
  • 7.28 Cell-Free DNA Used for Infectious Disease Testing
  • 7.29 One BioMed Raises $5M

8 The Global Market for Molecular Diagnostics Infectious Disease

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Syndrome - Overview
    • 8.2.1 Table - Global Market by Syndrome
    • 8.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Syndrome - Base Year
    • 8.2.4 Chart - Global Market by Syndrome - End Year
    • 8.2.5 Chart - Global Market by Syndrome - Share by Year
    • 8.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 8.3 Global Market by Plex - Overview
    • 8.3.1 Table - Global Market by Plex
    • 8.3.2 Chart - Global Market by Plex - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Plex - Base Year
    • 8.3.4 Chart - Global Market by Plex - End Year
    • 8.3.5 Chart - Global Market by Plex - Share by Year
    • 8.3.6 Chart - Global Market by Plex - Segments Growth
  • 8.4 Global Market by Place - Overview
    • 8.4.1 Table - Global Market by Place
    • 8.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Place - Base Year
    • 8.4.4 Chart - Global Market by Place - End Year
    • 8.4.5 Chart - Global Market by Place - Share by Year
    • 8.4.6 Chart - Global Market by Place - Segments Growth

9 Global MDx Infectious Disease Markets - By Syndrome

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Gastrointestinal
    • 9.2.1 Table Gastrointestinal - by Country
    • 9.2.2 Chart - Gastrointestinal Growth
  • 9.3 Blood
    • 9.3.1 Table Blood - by Country
    • 9.3.2 Chart - Blood Growth
  • 9.4 Meningitis/Encephalitis
    • 9.4.1 Table Meningitis/Encephalitis - by Country
    • 9.4.2 Chart - Meningitis/Encephalitis Growth
  • 9.5 Sexually Transmitted Disease
    • 9.5.1 Table Sexually Transmitted Disease - by Country
    • 9.5.2 Chart - Sexually Transmitted Disease Growth
  • 9.6 Other
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global MDx Markets for Infectious Disease - by Plex

  • 10.1 Single Plex
    • 10.1.1 Table Single Plex - by Country
    • 10.1.2 Chart - Single Plex Growth
  • 10.2 Duplex
    • 10.2.1 Table Duplex - by Country
    • 10.2.2 Chart - Duplex Growth
  • 10.3 Triplex
    • 10.3.1 Table Triplex - by Country
    • 10.3.2 Chart - Triplex Growth
  • 10.4 Multiplex Technology
    • 10.4.1 Table Multiplex - by Country
    • 10.4.2 Chart - Multiplex Growth

11 Global MDx Infectious Disease Markets - by Place

  • 11.1 Hospital Lab
    • 11.1.1 Table Hospital Lab - by Country
    • 11.1.2 Chart - Hospital Lab Growth
  • 11.2 Outpatient Lab
    • 11.2.1 Table Outpatient Lab - by Country
    • 11.2.2 Chart - Outpatient Lab Growth
  • 11.3 POC
    • 11.3.1 Table POC - by Country
    • 11.3.2 Chart - POC Growth
  • 11.4 Other Place
    • 11.4.1 Table Other Place- by Country
    • 11.4.2 Chart - Other Place Growth

12 Appendices

  • 12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 Classification of HIV Species
  • Table 2 HIV Tests - CMS Codes & Prices
  • Table 3 Current HIV Molecular Tests and Instruments Used
  • Table 4 HBV Tests - CMS Codes & Prices
  • Table 5 HCV Tests - CMS Codes & Prices
  • Table 6 HPV Clearance Rates
  • Table 7 HPV Tests - CMS Codes & Prices
  • Table 8 HPV Tests, Technology, Types
  • Table 9 Types of Influenza Tests
  • Table 10 Influenza Tests - CMS Codes & Prices
  • Table 11 FDA Cleared Molecular Assays for Influenza
  • Table 12 FDA Cleared NAAT CTGC Tests
  • Table 13 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 14 CTGC Tests - CMS Codes & Prices
  • Table 15 FDA Approved MDx Tests for Tuberculosis
  • Table 16 Tuberculosis Tests - CMS Codes & Prices
  • Table 17 FDA Approved Tests for MRSA
  • Table 18 MRSA Tests - CMS Codes & Prices
  • Table 19 FDA Approved Tests for VRE
  • Table 20 VRE Tests - CMS Codes & Prices
  • Table 21 FDA Approved Multiplex Assays
  • Table 22 Characteristics of Coronavirus Pandemic Infections
  • Table 23 COVID-19 Symptoms
  • Table 24 Market Players by Type
  • Table 25 Clinical Laboratory Departments and Segments
  • Table 26 Laboratory Management Focus - Different Approaches
  • Table 27 Key Segmentation Variables Going Forward
  • Table 28 Five Factors Driving Growth
  • Table 29 Four Factors Limiting Growth
  • Table 30 Key Diagnostic Laboratory Technology Trends
  • Table 31 - Global Market by Region
  • Table 32 Global Market by Syndrome
  • Table 33 Global Market by Plex
  • Table 34 Global Market by Place
  • Table 35 Respiratory by Country
  • Table 36 Gastrointestinal by Country
  • Table 37 Blood by Country
  • Table 38 Meningitis/Encephalitis by Country
  • Table 39 Sexually Transmitted Disease by Country
  • Table 40 Other by Country
  • Table 41 Single Plex by Country
  • Table 42 Duplex by Country
  • Table 43 Triplex by Country
  • Table 44 Multiplex by Country
  • Table 45 Hospital Lab by Country
  • Table 46 Outpatient Lab by Country
  • Table 47 POC by Country
  • Table 48 Other Place by Country
  • Table 49 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Map - Global Healthcare Spending Per Capita
  • Figure 2 The Lab Test Pie - Wholesale and Retail
  • Figure 3 HIV Virion
  • Figure 4 Diagram of the HIV Replication Cycle
  • Figure 5 The Structure of the HBV Virus
  • Figure 6 Hepatitis B Replication
  • Figure 7 Structure of the HCV Virus
  • Figure 8 HCV Replication Cycle
  • Figure 9 Structure of the Influenza Virion
  • Figure 10 Influenza Replication
  • Figure 11 Scanning Electronmicrograph of Tuberculosis
  • Figure 12 Percentage of World Population Over 65
  • Figure 13 Chart Infectious Disease Decline
  • Figure 14 Global Market Shares Chart
  • Figure 15 Global Market by Syndrome - Base vs. Final
  • Figure 16 Global Market by Syndrome Base Year
  • Figure 17 Global Market by Syndrome End Year
  • Figure 18 Syndrome Share by Year
  • Figure 19 Syndrome Segments Growth
  • Figure 20 Global Market by Plex - Base vs. Final
  • Figure 21 Global Market by Plex Base Year
  • Figure 22 Global Market by Plex End Year
  • Figure 23 Plex Share by Year
  • Figure 24 Plex Segments Growth
  • Figure 25 Global Market by Place - Base vs. Final
  • Figure 26 Global Market by Place Base Year
  • Figure 27 Global Market by Place End Year
  • Figure 28 Place Share by Year
  • Figure 29 Place Segments Growth
  • Figure 30 Respiratory Growth
  • Figure 31 Gastrointestinal Diagnostics Growth
  • Figure 32 Blood Growth
  • Figure 33 Meningitis/Encephalitis Growth
  • Figure 34 Sexually Transmitted Disease Growth
  • Figure 35 Other Growth
  • Figure 36 Single Plex Growth
  • Figure 37 Duplex Growth
  • Figure 38 Triplex Growth
  • Figure 39 Multiplex Growth
  • Figure 40 Hospital Lab Growth
  • Figure 41 Outpatient Lab Growth
  • Figure 42 POC Growth
  • Figure 43 Other Place Growth